Aristotle University Of Thessaloniki (AUTH)
Ασφάλεια και αποτελεσματικότητα της απιξαμπάνης ως προς την πρόληψη θρομβοεμβολικών επεισοδίων σε ενήλικες ασθενείς με συγγενή καρδιοπάθεια και κολπική μαρμαρυγή
Abstract
dc:descriptionIntroduction: In adults with congenital heart disease (ACHD), atrial fibrillation confers an increased risk of thromboembolic events. Limited data exist on non-vitamin K oral anticoagulant (NOAC) treatment for ACHD. We aimed to assess the effectiveness and safety of apixaban in ACHD patients with atrial fibrillation. Methods: Initially, we conducted a systematic review of evidence regarding the safety and efficacy of NOACs in CHD, until 2019. We then conducted a prospective, multicenter, observational study, from 2019 to 2023 (PROTECT-AR, NCT03854149). ACHD patients with atrial fibrillation or atrial flutter were included. The primary efficacy endpoint was the composite of stroke or thromboembolism. The primary safety endpoint was major bleeding. Patients who were previously on vitamin K antagonists (VKAs) before transitioning to apixaban served as a historical control group. Furthermore, in a subset of the population we conducted secondary analyses, correlating a) the anatomic and physiological classification (AP-ACHD) and b) arrhythmic symptoms burden (mEHRA) and health status (SF-36) with the composite of mortality and morbidity (stroke/thromboembolism, major or clinically relevant non-major bleeding, all-cause hospitalization). Results: In a systematic review of three observational studies up to 2019, totaling 766 ACHD patients receiving NOAC for primary or secondary prevention showed an annual rate of thromboembolic events at 0.98% (95% CI: 0.51–1.86) and an annual rate of major bleeding events at 1.74% (95% CI: 0.86–3.49) respectively. The PROTECT-AR study included 218 patients with ACHD and atrial fibrillation on apixaban (atrial fibrillation 76.1%, previous VKA users 34.9%) were included (mean age 51±17 years; 45.9% male; predominantly moderate complexity). Over a mean follow-up of 2.4±1.3 years, the rate of stroke or thromboembolism was 0.57% [95% confidence interval (CI): 0.15-1.55] and the rate of major bleeding was 1.52% [95% CI: 0.71-2.88] per patient-year, respectively. In the subset of patients who were previously on VKA, the risk of the primary endpoints did not differ significantly between apixaban and VKA-treatment periods. In secondary analyses, the adjuster hazard ratio for the composite endpoint of mortality and morbidity in patients with physiological class C and D was 1.79 (95% CI: 0.69-4.67) και 8.15 (95% CI: 1.52-43.59), as compared with physiological class B, respectively. The risk in patients with anatomical class II and III was 1.12 (95% CI 0.37-3.41) and 1.06 (95% CI 0.24-4.63), as compared with anatomical class I, respectively. The adjusted risk of the composite endpoint was significantly higher in patients with SF-36 PCS ≤ 50 compared with those with PCS > 50 (HR, 1.98; 95% CI, 1.02–3.84). The mEHRA score was incrementally associated with a higher risk of the composite endpoint (HR = 1.44 per 1 unit increase in score; 95% CI, 1.03–2.00). Conclusion: In ACHD patients with atrial fibrillation on routine apixaban treatment, the risk of major thromboembolic and bleeding events was low. Among prior VKA users, the risk of adverse events during the apixaban-treatment period was comparable to that during the VKA-treatment period. Furthermore, in ACHD patients with atrial fibrillation the physiological component of the AP-ACHD classification, the SF-36 PCS ≤ 50 and mEHRA scores predicted an increased risk of adverse events.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kartas, Anastasios
- Κάρτας, Αναστάσιος
Subjects
dc:subject × 12- Κολπική μαρμαρυγή
- Καρδιοπάθειες, Συγγενείς
- Αίμα, Αντιπηκτικοί παράγοντες
- Atrial fibrillation
- Congenital heart diseases ( CHD)
- Anticoagulants
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54160